These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
3. Anticalcification and antiresorption effects of bisacylphosphonates. Van Gelder JM; Breuer E; Ornoy A; Schlossman A; Patlas N; Golomb G Bone; 1995 May; 16(5):511-20. PubMed ID: 7654466 [TBL] [Abstract][Full Text] [Related]
4. Relative binding affinities of bisphosphonates for human bone and relationship to antiresorptive efficacy. Leu CT; Luegmayr E; Freedman LP; Rodan GA; Reszka AA Bone; 2006 May; 38(5):628-36. PubMed ID: 16185944 [TBL] [Abstract][Full Text] [Related]
5. Alendronate distributed on bone surfaces inhibits osteoclastic bone resorption in vitro and in experimental hypercalcemia models. Azuma Y; Sato H; Oue Y; Okabe K; Ohta T; Tsuchimoto M; Kiyoki M Bone; 1995 Feb; 16(2):235-45. PubMed ID: 7756053 [TBL] [Abstract][Full Text] [Related]
6. Bisphosphonates: the first 40 years. Russell RG Bone; 2011 Jul; 49(1):2-19. PubMed ID: 21555003 [TBL] [Abstract][Full Text] [Related]
7. Structurally different bisphosphonates exert opposing effects on alkaline phosphatase and mineralization in marrow osteoprogenitors. Klein BY; Ben-Bassat H; Breuer E; Solomon V; Golomb G J Cell Biochem; 1998 Feb; 68(2):186-94. PubMed ID: 9443074 [TBL] [Abstract][Full Text] [Related]
8. Studies on novel bone resorption inhibitors. II. Synthesis and pharmacological activities of fused aza-heteroarylbisphosphonate derivatives. Takeuchi M; Sakamoto S; Kawamuki K; Kurihara H; Nakahara H; Isomura Y Chem Pharm Bull (Tokyo); 1998 Nov; 46(11):1703-9. PubMed ID: 9845953 [TBL] [Abstract][Full Text] [Related]
9. Highly potent geminal bisphosphonates. From pamidronate disodium (Aredia) to zoledronic acid (Zometa). Widler L; Jaeggi KA; Glatt M; Müller K; Bachmann R; Bisping M; Born AR; Cortesi R; Guiglia G; Jeker H; Klein R; Ramseier U; Schmid J; Schreiber G; Seltenmeyer Y; Green JR J Med Chem; 2002 Aug; 45(17):3721-38. PubMed ID: 12166945 [TBL] [Abstract][Full Text] [Related]
10. In vitro and in vivo effects of tetrakisphosphonates on bone resorption, tumor osteolysis, ectopic calcification, and macrophages. Van Gelder JM; Breuer E; Schlossman A; Ornoy A; Mönkkönen J; Similä J; Klenner T; Stadler H; Krempien B; Patlas N; Golomb G J Pharm Sci; 1997 Mar; 86(3):283-9. PubMed ID: 9050794 [TBL] [Abstract][Full Text] [Related]
11. Synthesis, characterization and biodistribution of bisphosphonates Sm-153 complexes: correlation with molecular modeling interaction studies. Neves M; Gano L; Pereira N; Costa MC; Costa MR; Chandia M; Rosado M; Fausto R Nucl Med Biol; 2002 Apr; 29(3):329-38. PubMed ID: 11929703 [TBL] [Abstract][Full Text] [Related]
12. Studies on novel bone resorption inhibitors. I. Synthesis and pharmacological activities of aminomethylenebisphosphonate derivatives. Takeuchi M; Sakamoto S; Yoshida M; Abe T; Isomura Y Chem Pharm Bull (Tokyo); 1993 Apr; 41(4):688-93. PubMed ID: 8508470 [TBL] [Abstract][Full Text] [Related]
13. A quantitative structure-activity relationship and pharmacophore modeling investigation of aryl-X and heterocyclic bisphosphonates as bone resorption agents. Kotsikorou E; Oldfield E J Med Chem; 2003 Jul; 46(14):2932-44. PubMed ID: 12825934 [TBL] [Abstract][Full Text] [Related]
14. Preparation and evaluation of chitosan microspheres containing bisphosphonates. Patashnik S; Rabinovich L; Golomb G J Drug Target; 1997; 4(6):371-80. PubMed ID: 9239577 [TBL] [Abstract][Full Text] [Related]
15. Bone-specific alkaline phosphatase activity is inhibited by bisphosphonates: role of divalent cations. Vaisman DN; McCarthy AD; Cortizo AM Biol Trace Elem Res; 2005 May; 104(2):131-40. PubMed ID: 15894813 [TBL] [Abstract][Full Text] [Related]
16. The effects of nitrogen-containing bisphosphonates on human epithelial (Caco-2) cells, an in vitro model for intestinal epithelium. Twiss IM; Pas O; Ramp-Koopmanschap W; Den Hartigh J; Vermeij P J Bone Miner Res; 1999 May; 14(5):784-91. PubMed ID: 10320527 [TBL] [Abstract][Full Text] [Related]
17. Nonclinical model for assessing gastric effects of bisphosphonates. Blank MA; Ems BL; Gibson GW; Myers WR; Berman SK; Phipps RJ; Smith PN Dig Dis Sci; 1997 Feb; 42(2):281-8. PubMed ID: 9052507 [TBL] [Abstract][Full Text] [Related]
18. A randomized clinical trial comparing oral alendronate and intravenous pamidronate for the treatment of Paget's disease of bone. Walsh JP; Ward LC; Stewart GO; Will RK; Criddle RA; Prince RL; Stuckey BG; Dhaliwal SS; Bhagat CI; Retallack RW; Kent GN; Drury PJ; Vasikaran S; Gutteridge DH Bone; 2004 Apr; 34(4):747-54. PubMed ID: 15050907 [TBL] [Abstract][Full Text] [Related]
19. Effect of bisphosphonates on vascular calcification and bone metabolism in experimental renal failure. Lomashvili KA; Monier-Faugere MC; Wang X; Malluche HH; O'Neill WC Kidney Int; 2009 Mar; 75(6):617-25. PubMed ID: 19129793 [TBL] [Abstract][Full Text] [Related]
20. In vitro and in vivo anticalcification effects of novel bishydroxyiminophosphonates. Golomb G; Schlossman A; Eitan Y; Saadeh H; Van Gelder JM; Breuer E J Pharm Sci; 1992 Oct; 81(10):1004-7. PubMed ID: 1432609 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]